Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumour necrosis factor inhibitors.

Peter T Nash1, Timothy H J Florin

  • 1Rheumatology Research Unit, Department of Medicine, University of Queensland, PO BOX 59, Cottontree, QLD 4558, Australia. pnash@tpg.com.au

The Medical Journal of Australia
|August 16, 2005
PubMed
Summary

Tumour necrosis factor-alpha (TNF-alpha) inhibitors effectively treat inflammatory and rheumatic diseases by reducing symptoms and damage. However, side effects like infections and potential long-term risks require careful monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Predicts Initial Biologic Disease-Modifying Antirheumatic Drug Failure in Psoriatic Arthritis and How Common Is It?

The Journal of rheumatology·2025
Same author

Advances in Thiopurine Drug Delivery: The Current State-of-the-Art.

European journal of drug metabolism and pharmacokinetics·2021
Same author

A well-tolerated and rapidly acting thiopurine for IBD?

Drug discovery today·2018
Same author

Microbial metabolism of thiopurines: A method to measure thioguanine nucleotides.

Journal of microbiological methods·2016
Same author

Reply.

Arthritis care & research·2015
Same author

Treatment Algorithms in Systemic Lupus Erythematosus.

Arthritis care & research·2015

Area of Science:

  • Immunology
  • Rheumatology
  • Gastroenterology

Background:

  • Tumour necrosis factor-alpha (TNF-alpha) is a key cytokine in chronic inflammatory and rheumatic diseases.
  • Conditions include Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Purpose of the Study:

  • To review the efficacy and safety of TNF inhibitors in treating rheumatic diseases.
  • To discuss the limitations and side effects associated with TNF inhibitor therapy.

Main Methods:

  • Review of controlled trials on TNF inhibitors (etanercept, infliximab, adalimumab).
  • Analysis of clinical outcomes, including symptom reduction, functional improvement, and damage.
  • Evaluation of adverse events and long-term safety concerns.

Related Experiment Videos

Main Results:

  • TNF inhibitors significantly improve symptoms, function, and quality of life in rheumatoid diseases.
  • Etanercept is ineffective in Crohn's disease.
  • Adverse events include injection site reactions, infections (e.g., tuberculosis reactivation), and potential long-term risks.

Conclusions:

  • TNF inhibitors are effective treatments for several chronic inflammatory and rheumatic conditions.
  • Careful patient selection and monitoring are crucial due to potential side effects and varying efficacy.
  • The high cost and continuous treatment requirement present challenges.